BioMarin Surges 19% on $4.8B Amicus Acquisition: A Rare Disease Powerhouse Emerges

Summary
• BioMarin (BMRN) rockets 19.15% intraday, trading at $61.90 after announcing a $4.8B all-cash acquisition of Amicus Therapeutics.
• The deal adds Galafold and Pombiliti + Opfolda, two high-growth rare disease therapies, with $599M in trailing revenue.
• Technicals show a 22.55 P/E ratio, 6.77% turnover rate, and a 52-week high of $73.51.

BioMarin’s stock is surging on a transformative $4.8B acquisition of Amicus Therapeutics, a rare disease biotech with two blockbuster therapies. The deal, announced Friday, has triggered a 19.15% intraday rally, pushing BMRN to $61.90—its highest level since late 2024. With a 52-week high of $73.51 in sight, the move reflects investor optimism over expanded revenue streams and a stronger rare disease portfolio.

Strategic Acquisition Drives 19% Surge
BioMarin’s 19.15% intraday jump is directly tied to its $4.8B acquisition of Amicus Therapeutics, announced on December 19. The all-cash deal adds Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease), two high-growth therapies with $599M in combined revenue over the past four quarters. The acquisition is expected to be accretive to non-GAAP EPS in the first 12 months post-close and substantially accretive by 2027. BioMarin’s CEO emphasized the strategic fit, citing Amicus’ global commercial potential and BioMarin’s manufacturing scale. The deal also resolves pending Galafold patent litigation, securing U.S. exclusivity through 2037. With $2B in cash and $3.7B in debt financing, the transaction is structured to strengthen BioMarin’s balance sheet while expanding its rare disease footprint.

Biotech Sector Rally: Amgen Leads 1.05% Gains
The biotech sector is broadly positive, with Amgen (AMGN) rising 1.05% as a sector leader. BioMarin’s 19.15% surge far outpaces the sector’s average, reflecting the unique catalyst of a transformative acquisition. While Amgen’s growth is driven by its oncology and biosimilars portfolio, BioMarin’s move into Fabry and Pompe disease positions it as a consolidator in rare diseases. The sector’s optimism is further fueled by positive news on gene therapies and obesity treatments, but BioMarin’s deal stands out for its immediate revenue accretion and long-term EPS potential.

Options Playbook: High-Leverage Calls for a Bullish Bet
• RSI: 20.2985 (oversold)
• MACD: -0.5139 (bearish), Signal Line: -0.2296
• Bollinger Bands: Upper $56.55, Middle $53.78, Lower $51.00
• 200D MA: $57.99 (above current price)
• Support/Resistance: 30D support $51.75, 200D resistance $58.29

BioMarin’s technicals suggest a short-term bearish trend but a long-term bullish setup. The RSI at 20.2985 indicates oversold conditions, while the 200-day MA at $57.99 is a key resistance level. With the stock trading near its 52-week high of $73.51, bulls are betting on continued momentum. The options chain offers high-leverage calls for aggressive positioning:

Top Option 1: BMRN20260116C60
• Type: Call
• Strike: $60
• Expiration: 2026-01-16
• IV: 44.51% (moderate)
• Leverage Ratio: 15.39%
• Delta: 0.6159 (moderate sensitivity)
• Theta: -0.0991 (high time decay)
• Gamma: 0.0494 (high sensitivity to price moves)
• Turnover: $219,581
• Payoff at 5% Upside (65): $5.00 per contract
This call offers a 15.39% leverage ratio and high gamma, making it ideal for a 5% upside scenario. The moderate IV and high turnover ensure liquidity, while the high theta suggests rapid time decay, favoring quick moves.

Top Option 2: BMRN20260116C62.5
• Type: Call
• Strike: $62.5
• Expiration: 2026-01-16
• IV: 35.42% (moderate)
• Leverage Ratio: 29.04%
• Delta: 0.4731 (moderate sensitivity)
• Theta: -0.0806 (high time decay)
• Gamma: 0.0647 (very high sensitivity)
• Turnover: $45,914
• Payoff at 5% Upside (65): $2.50 per contract
This option’s 29.04% leverage ratio and 0.0647 gamma make it a high-gamma play for a 5% move. The moderate IV and high gamma suggest it could benefit from a sharp price increase, though the lower turnover may limit liquidity.

Action: Aggressive bulls should prioritize BMRN20260116C60 for a 5% upside bet. If the stock breaks above $65, consider rolling into higher strikes. Watch the 200D MA at $57.99 as a critical support level.

Backtest Biomarin Stock Performance
The backtest of BMRN's performance after a 19% intraday surge from 2022 to the present reveals mixed results. While the stock experienced a maximum return of 6.26% over 30 days, the win rates for both 3-day and 10-day periods are below 50%, indicating that most short-term investments did not yield positive returns.

BioMarin’s Rare Disease Bet: A High-Conviction Trade
BioMarin’s 19.15% surge is a watershed moment for the rare disease sector, driven by a $4.8B acquisition that adds two high-growth therapies and resolves patent risks. The stock’s technicals suggest a short-term bearish trend but a long-term bullish setup, with the 200D MA at $57.99 acting as a key support. Investors should monitor the 52-week high of $73.51 and the 200D resistance at $58.29. The sector leader, Amgen (AMGN), is up 1.05%, reinforcing the biotech rally. For a high-conviction trade, BMRN20260116C60 offers a compelling leveraged play on a 5% upside. If the stock breaks above $65, the 200D MA could become a catalyst for further gains. Watch for regulatory updates and earnings guidance post-transaction close in Q2 2026.